A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer

NCT00583830 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

BIOLOGICAL: Mapatumumab
BIOLOGICAL: Mapatumumab
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Human Genome Sciences Inc.